Literature DB >> 18226769

Cystatin C concentration as a predictor of systolic and diastolic heart failure.

Andrew Moran1, Ronit Katz, Nicolas L Smith, Linda F Fried, Mark J Sarnak, Stephen L Seliger, Bruce Psaty, David S Siscovick, John S Gottdiener, Michael G Shlipak.   

Abstract

BACKGROUND: Risk factors for heart failure (HF) may differ according to ejection fraction (EF). Higher cystatin C, a marker of kidney dysfunction, is associated with incident HF, but previous studies did not determine EF at diagnosis. We hypothesized that kidney dysfunction would predict diastolic HF (DHF) better than systolic HF (SHF) in the Cardiovascular Health Study. METHODS AND
RESULTS: Cystatin C was measured in 4453 participants without HF at baseline. Incident HF was categorized as DHF (EF > or = 50%) or SHF (EF < 50%). We compared the association of cystatin C with the risk for DHF and SHF, after adjustment for age, sex, race, medications, and HF risk factors. During 8 years of follow-up, 167 participants developed DHF and 206 participants developed SHF. After adjustment, sequentially higher quartiles of cystatin C were associated with risk for SHF (competing risks hazard ratios 1.0 [reference], 1.99 [95% confidence interval 1.14-3.48], 2.32 [1.32-4.07], 3.17 [1.82-5.50], P for trend < .001). The risk for DHF was apparent only at the highest cystatin C quartile (hazard ratios 1.0 [reference], 1.09 [0.62-1.89], 1.08 [0.61-1.93], and 1.83 [1.07-3.11]).
CONCLUSIONS: Cystatin C levels are linearly associated with the incidence of systolic HF, whereas only the highest concentrations of cystatin C predict diastolic HF.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18226769      PMCID: PMC2258307          DOI: 10.1016/j.cardfail.2007.09.002

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  39 in total

1.  Development, prevention, and potential reversal of left ventricular hypertrophy in chronic kidney disease.

Authors:  Lawrence P McMahon; Simon D Roger; Adeera Levin
Journal:  J Am Soc Nephrol       Date:  2004-06       Impact factor: 10.121

2.  Chronic kidney disease predicts cardiovascular disease.

Authors:  Thomas H Hostetter
Journal:  N Engl J Med       Date:  2004-09-23       Impact factor: 91.245

Review 3.  Vascular calcification in chronic kidney disease.

Authors:  William G Goodman; Gerard London; Kerstin Amann; Geoffrey A Block; Cecilia Giachelli; Keith A Hruska; Markus Ketteler; Adeera Levin; Ziad Massy; David A McCarron; Paolo Raggi; Catherine Mary Shanahan; Noriaki Yorioka
Journal:  Am J Kidney Dis       Date:  2004-03       Impact factor: 8.860

4.  The Cardiovascular Health Study: design and rationale.

Authors:  L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman
Journal:  Ann Epidemiol       Date:  1991-02       Impact factor: 3.797

5.  Mild renal insufficiency and risk of congestive heart failure in men and women > or =70 years of age.

Authors:  Claudia U Chae; Christine M Albert; Robert J Glynn; Jack M Guralnik; Gary C Curhan
Journal:  Am J Cardiol       Date:  2003-09-15       Impact factor: 2.778

6.  Predictors of heart failure among women with coronary disease.

Authors:  Kirsten Bibbins-Domingo; Feng Lin; Eric Vittinghoff; Elizabeth Barrett-Connor; Stephen B Hulley; Deborah Grady; Michael G Shlipak
Journal:  Circulation       Date:  2004-09-07       Impact factor: 29.690

7.  Human evidence that the cystatin C gene is implicated in focal progression of coronary artery disease.

Authors:  Per Eriksson; Hiroyuki Deguchi; Ann Samnegård; Pia Lundman; Susanna Boquist; Per Tornvall; Carl-Göran Ericsson; Lott Bergstrand; Lars-Olof Hansson; Shu Ye; Anders Hamsten
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-01-15       Impact factor: 8.311

8.  Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality.

Authors:  Gérard M London; Alain P Guérin; Sylvain J Marchais; Fabien Métivier; Bruno Pannier; Hasan Adda
Journal:  Nephrol Dial Transplant       Date:  2003-09       Impact factor: 5.992

9.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.

Authors:  S Yusuf; B Pitt; C E Davis; W B Hood; J N Cohn
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

10.  Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion.

Authors:  R J Cody; S A Atlas; J H Laragh; S H Kubo; A B Covit; K S Ryman; A Shaknovich; K Pondolfino; M Clark; M J Camargo
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

View more
  14 in total

Review 1.  Association of cystatin C with adverse outcomes.

Authors:  Magdalena Madero; Mark J Sarnak
Journal:  Curr Opin Nephrol Hypertens       Date:  2009-05       Impact factor: 2.894

Review 2.  Circulating biomarkers in patients with heart failure and preserved ejection fraction.

Authors:  Eileen O'Meara; Simon de Denus; Jean-Lucien Rouleau; Akshay Desai
Journal:  Curr Heart Fail Rep       Date:  2013-12

3.  Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis.

Authors:  John G F Cleland; Valentina Carubelli; Teresa Castiello; Ashraf Yassin; Pierpaolo Pellicori; Renjith Antony
Journal:  Heart Fail Rev       Date:  2012-03       Impact factor: 4.214

4.  Cystatin C increases in cardiac injury: a role in extracellular matrix protein modulation.

Authors:  Lifang Xie; Jerome Terrand; Beibei Xu; George Tsaprailis; Jean Boyer; Qin M Chen
Journal:  Cardiovasc Res       Date:  2010-05-20       Impact factor: 10.787

5.  Crosstalk of Various Biomarkers That Might Provide Prompt Identification of Acute or Chronic Cardiorenal Syndromes.

Authors:  Danijela Tasić; Sonja Radenkovic; Dijana Stojanovic; Maja Milojkovic; Miodrag Stojanovic; Marina Deljanin Ilic; Gordana Kocic
Journal:  Cardiorenal Med       Date:  2015-11-11       Impact factor: 2.041

Review 6.  Cardiorenal [corrected] syndrome: an emerging problem in pediatric critical care.

Authors:  John Lynn Jefferies; Stuart L Goldstein
Journal:  Pediatr Nephrol       Date:  2012-07-18       Impact factor: 3.714

Review 7.  Cystatin C: a step forward in assessing kidney function and cardiovascular risk.

Authors:  Johan Lassus; Veli-Pekka Harjola
Journal:  Heart Fail Rev       Date:  2012-03       Impact factor: 4.214

8.  Diminished renal function and the incidence of heart failure.

Authors:  Johan Arnlöv
Journal:  Curr Cardiol Rev       Date:  2009-08

9.  Differential prognostic utility of NTproBNP and Cystatin C in patients with acute exacerbation of chronic pulmonary disease.

Authors:  Juan I Pérez-Calvo; Marta Sánchez-Marteles; Francisco-José Ruiz-Ruiz; José-Luis Morales-Rull; José-Antonio Nieto-Rodríguez
Journal:  JRSM Short Rep       Date:  2010-10-21

10.  The multi-biomarker approach for heart failure in patients with hypertension.

Authors:  Agata Bielecka-Dabrowa; Anna Gluba-Brzózka; Marta Michalska-Kasiczak; Małgorzata Misztal; Jacek Rysz; Maciej Banach
Journal:  Int J Mol Sci       Date:  2015-05-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.